Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPLP1 | P05386 | 5/20 | 0.35 |
| ▸ | RPLP0 | P05388 | 5/20 | 0.35 |
| ▸ | RPS17 | P08708 | 5/20 | 0.35 |
| ▸ | RPSA | P08865 | 5/20 | 0.35 |
| ▸ | RPS2 | P15880 | 5/20 | 0.35 |
| ▸ | RPL35A | P18077 | 5/20 | 0.35 |
| ▸ | RPL7 | P18124 | 5/20 | 0.35 |
| ▸ | RPL17 | P18621 | 5/20 | 0.35 |
| ▸ | RPS4Y1 | P22090 | 5/20 | 0.35 |
| ▸ | RPS3 | P23396 | 5/20 | 0.35 |
| ▸ | RPS12 | P25398 | 5/20 | 0.35 |
| ▸ | RPL13 | P26373 | 5/20 | 0.35 |
| ▸ | RPL10 | P27635 | 5/20 | 0.35 |
| ▸ | RPL12 | P30050 | 5/20 | 0.35 |
| ▸ | RPL9; RPL9P7; RPL9P8; RPL9P9 | P32969 | 5/20 | 0.35 |
| ▸ | RPL22 | P35268 | 5/20 | 0.35 |
| ▸ | RPL4 | P36578 | 5/20 | 0.35 |
| ▸ | RPS19 | P39019 | 5/20 | 0.35 |
| ▸ | RPL3 | P39023 | 5/20 | 0.35 |
| ▸ | RPL13A | P40429 | 5/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4066234 | 0.95 | P2RX7 (0.35) | P2RX7POLBCCR5ALDH2 | |
| SCHEMBL4065883 | 0.94 | CCR5 (0.36) | RPLP1RPLP0RPS17RPSARPS2 | |
| SCHEMBL4065035 | 0.91 | P2RX7 (0.36) | P2RX7POLBCCR5ALDH2 | |
| SCHEMBL4065384 | 0.89 | CCR5 (0.36) | POLBCCR5ALDH2 | |
| SCHEMBL4066927 | 0.84 | CCR5 (0.37) | POLBCCR5ALDH2 | |
| SCHEMBL7024502 | 0.84 | POLB (0.40) | P2RX7POLB | |
| SCHEMBL4069138 | 0.83 | CXCR4 (0.40) | — | |
| SCHEMBL4063770 | 0.80 | P2RX7 (0.36) | P2RX7POLBALDH2 | |
| SCHEMBL4064110 | 0.80 | P2RX7 (0.36) | P2RX7POLBALDH2 | |
| SCHEMBL6888272 | 0.78 | P2RX7 (0.34) | P2RX7POLBCCR5ALDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090846-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | GENZYME CORPORATION | 2008-04-17 | — | — | US | claimed |
| EP-1317443-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC (CA) | 2009-01-14 | — | — | EP | disclosed |
| EP-1317443-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC (CA) | 2009-01-14 | — | — | EP | disclosed |
| US-20080090846-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | GENZYME CORPORATION | 2008-04-17 | — | — | US | disclosed |
| US-20080090846-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | GENZYME CORPORATION | 2008-04-17 | — | — | US | disclosed |
| US-20080090846-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | GENZYME CORPORATION | 2008-04-17 | — | — | US | disclosed |
| US-7312234-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED (CA) | 2007-12-25 | — | — | US | disclosed |
| US-7312234-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED (CA) | 2007-12-25 | — | — | US | disclosed |
| US-7312234-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED (CA) | 2007-12-25 | — | — | US | disclosed |
| US-20050026942-A1 | Chemokine receptor binding heterocyclic compounds | ANORMED (CA) | 2005-02-03 | — | — | US | disclosed |
| US-6835731-B2 | Viricides; antiinflammatory agents; antiallergens; antiarthritic agents | ANORMED, INC. (CA) | 2004-12-28 | — | — | US | disclosed |
| EP-1317443-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2003-06-11 | — | — | EP | disclosed |
| US-20020147192-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2002-10-10 | — | — | US | disclosed |
| WO-2002022599-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147192-A1 | Chemokine receptor binding heterocyclic compounds | CCR2, CXCR3, ACKR3 | RPLP1 2855/4885RPLP0 3204/4885RPS17 3759/4885 |
| US-20080090846-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | CCR2, CXCR3, ACKR3 | RPLP1 2855/4885RPLP0 3204/4885RPS17 3759/4885 |
| US-20050026942-A1 | Chemokine receptor binding heterocyclic compounds | CCR2, CXCR3, ACKR3 | RPLP1 2855/4885RPLP0 3204/4885RPS17 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.